Tirzepatide (Zepbound) is a dual incretin therapy that targets both GLP-1 and GIP receptors to promote significant weight loss. It outperforms older GLP-1 drugs like semaglutide, with users losing up to 22.4% of body weight. Learn how it works, what to expect, and who it's for.
